Immuneering appoints Igor Matushansky as CMO

Today, Cambridge, USA-based clinical-stage oncology company Immuneering (Nasdaq: IMRX) announced the appointment of Dr Igor Matushansky as chief medical officer (CMO).

In this role, Dr Matushansky will direct Immuneering’s clinical activities, providing medical and operational leadership for the company’s development programs including an ongoing Phase IIa study of its lead program IMM-1-104 in pancreatic cancer, lung cancer, and melanoma.

Dr Matushansky joins Immuneering with more than 13 years of experience leading clinical, medical, translational, and regulatory functions in biotech and pharma. He most recently served as CMO at Sail Biomedicines, a Flagship Pioneering company. Prior to that, he was senior vice president and global head of oncology development at French drugmaker Ipsen (Euronext: IPN), working extensively on pancreatic cancer treatment regimens. He also held leadership roles at Hookipa Pharma, Daiichi Sankyo (TYO: 4568), and Novartis (NOVN: VX), overseeing oncology research and early development programs. Dr Matushansky began his career in academia at Columbia University Medical Center, where he founded and directed a sarcoma center.